(S)-Nicotine Synthesis via Enzymatic Reduction and Methylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing (S)-nicotine face challenges in achieving high enantiomeric and chemical purity, particularly in synthetic processes, as existing processes often involve racemic mix resolution or enzyme-based methods with variable selectivity and efficiency.
Innovation Solution
A process involving the reduction of myosmine with an enzyme having imine reductase activity to form (S)-nornicotine, followed by methylation to produce (S)-nicotine, which achieves high enantiomeric and chemical purity without the need for racemic mix resolution, using enzymes like IRED_A and IRED_B, and cofactors such as NADH or NADPH.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If nicotine is obtained by extraction from tobacco leaves, then the process is simple and direct, but the chemical purity is less than 95% due to the presence of related alkaloid impurities
Solution Approach 1:
The patent replaces the mechanical extraction process with an enzymatic biological system. The enzyme catalyzes the conversion of myosmine to (S)-nornicotine, which is then methylated to produce (S)-nicotine. This biochemical pathway achieves high enantiomeric and chemical purity without the need for complex separation processes required in extraction methods.
2Manufacturing precision
If a racemic mix of nicotine is made and subsequently resolved to obtain the (S) enantiomer, then the process can produce enantiomerically pure nicotine, but the process complexity increases
Solution Approach 1:
The patent applies preliminary action by using an enzyme to catalyze the formation of the (S) enantiomer from the beginning of the synthesis pathway. The enzyme selectively converts myosmine to (S)-nornicotine, which then proceeds to form (S)-nicotine. This prevents the formation of the (R) enantiomer entirely, eliminating the need for subsequent resolution steps.
3Productivity
If existing synthetic processes are used to produce (S)-nicotine, then nicotine can be produced synthetically, but achieving high enantiomeric and chemical purity remains a challenge
Solution Approach 1:
The patent changes the key parameter of selectivity by introducing an enzyme catalyst. The enzyme's active site is designed to recognize and bind myosmine in a specific orientation, enabling highly selective conversion to the (S) enantiomer. This enzymatic parameter change achieves both high productivity and high enantiomeric excess (>90%) and chemical purity (>98%) simultaneously.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process ensures a high enantiomeric excess and chemical purity of (S)-nicotine, reducing the risk of impurity-related negative effects and providing a convenient manufacturing route, with (S)-nicotine produced having an enantiomeric excess of at least 90% and chemical purity of at least 98%, suitable for pharmaceutical and tobacco industry standards.
Implementation Method 1
reducing myosmine with an enzyme with imine reductase activity to form (S)-nornicotine
Implementation Method 2
methylating the (S)-nornicotine formed from step (i) to form (S)-nicotine
Data Source
AI summary
A process for synthetically producing (S)-nicotine ([(S)-3-(1-methylpyrrolidin-2-yl) pyridine]) is provided.